PMV Pharmaceuticals(PMVP)
$0.88-0.43 (-33.13%)
PMVP
PMV Pharmaceuticals financials statements
$0.88
At close:-0.43 (-33.13%)
Want to see PMVP full AI Analyst Report?
PMV Pharmaceuticals (PMVP) Ratios
181 Followers
PMV Pharmaceuticals Ratios
PMVP's free cash flow for Q3 2026 was $-18.18M. For the 2026 fiscal year, PMVP's free cash flow was increased by $0.00 and operating cash flow was $-18.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.09 | 12.22 | 14.78 | 22.80 | 24.66 |
| Quick Ratio | 10.09 | 12.22 | 14.78 | 22.80 | 24.66 |
| Cash Ratio | 3.33 | 2.84 | 2.69 | 10.00 | 14.11 |
| Solvency Ratio | -6.55 | -3.79 | -2.56 | -2.99 | -2.46 |
| Operating Cash Flow Ratio | -6.45 | -3.57 | -3.97 | -5.89 | -3.81 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -145.69 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 103.38M | $ 160.45M | $ 180.95M | $ 222.73M | $ 278.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.05 | 0.05 | 0.03 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.06 | 0.06 | 0.04 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.06 | 0.05 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 1.09 | 1.12 | 1.10 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | -163.54 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.02 | 0.28 | 0.31 | 0.25 |
| Net Debt to EBITDA | 0.47 | 0.54 | 0.36 | 1.30 | 2.85 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 97.28% | 78.48% | 100.00% | 99.99% | 100.04% |
| EBT Per EBIT | 92.70% | 87.55% | 86.06% | 95.18% | 99.19% |
| Return on Assets (ROA) | -66.70% | -30.69% | -27.35% | -27.12% | -17.45% |
| Return on Equity (ROE) | -74.24% | -33.34% | -30.56% | -29.80% | -18.75% |
| Return on Capital Employed (ROCE) | -81.99% | -48.30% | -33.65% | -29.69% | -18.25% |
| Return on Invested Capital (ROIC) | -79.45% | -37.83% | -33.53% | -29.63% | -18.23% |
| Return on Tangible Assets | -66.70% | -30.69% | -27.35% | -27.12% | -17.45% |
| Earnings Yield | -118.37% | -75.38% | -46.33% | -18.48% | -5.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.17 | 0.39 | 0.22 | 0.40 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2099.07 | -939.94 | -1682.37 | -908.65 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 2099.07 | 939.94 | 1682.37 | 908.65 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.40 | -0.99 | -1.16 | -1.40 | -1.03 |
| Free Cash Flow Per Share | -1.40 | -1.01 | -1.18 | -1.57 | -1.06 |
| Dividend Paid and CapEx Coverage Ratio | -2537.14 | -78.29 | -57.86 | -7.99 | -34.52 |
| Capital Expenditure Coverage Ratio | -2537.14 | -78.29 | -57.86 | -7.99 | -34.52 |
| Operating Cash Flow Coverage Ratio | -87.80 | -43.09 | -4.19 | -4.56 | -4.16 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -112.07% | -66.69% | -38.04% | -18.09% | -4.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.84 | -1.33 | -2.16 | -5.41 | -18.03 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.63 | 0.44 | 0.66 | 1.61 | 3.38 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.89 | -1.50 | -2.63 | -5.53 | -21.76 |
| Price-to-Operating Cash Flow Ratio | -0.89 | -1.52 | -2.67 | -6.22 | -22.39 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 0.06 | 0.20 | -0.21 | 0.39 |
| Enterprise Value Multiple | -0.36 | -0.52 | -1.84 | -4.16 | -15.59 |
| Enterprise Value | 28.53M | 38.20M | 124.42M | 302.35M | 881.41M |
| EV to EBITDA | -0.36 | -0.52 | -1.84 | -4.16 | -15.59 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.39 | -0.74 | -2.20 | -4.21 | -18.39 |
| EV to Operating Cash Flow | -0.39 | -0.74 | -2.24 | -4.74 | -18.93 |
| Tangible Book Value Per Share | 1.99 | 3.41 | 4.70 | 5.40 | 6.84 |
| Shareholders’ Equity Per Share | 1.99 | 3.41 | 4.70 | 5.40 | 6.84 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.22 | -0.00 | 0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.48 | -1.14 | -1.44 | -1.61 | -1.28 |
| Tax Burden | 0.97 | 0.78 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.95 | 0.87 | 0.81 | 0.87 | 0.81 |
Currency in USD

